GNQ’s Drug Assessment Platform Enhances Non-Small Cell Lung Cancer Treatment by Extending Efficacy Beyond Universal Resistance Barrier
GNQ Insilico, Inc. (“GNQ” or “the Company”), a TechBio platform company, demonstrated the advanced capabilities of its AI-powered Drug Assessment Platform in addressing critical treatment optimization challenges for patients with Non-Small Cell Lung Cancer (NSCLC). NSCLC remains the leading cause of cancer-related mortality, representing 85% of all lung cancer cases[1]. Patients face significant treatment challenges […]